MedPath

A trial to assess the effectiveness of inhaled glycopyrrolate in improving the visual clarity during insertion of endotracheal tube with the help of fiberscope.

Completed
Conditions
Medical and Surgical,
Registration Number
CTRI/2022/03/041048
Lead Sponsor
AIIMS PATNA
Brief Summary

In this study, inhaled glycopyrrolate is used as a premedication inorder to reduce the airway secretions to improve the fibreoptic visual field during nasotracheal intubation.

According to DAS guidelines for awake tracheal intubation,use of systemic antisialogogue is not mandatory, however its also stated that fibrescopy view  may  be improved with antisialogogue.

Inhaled glycopyrrolate ,currently approved for management of COPD has not been evaluated for its anti secretory effect.Hence usage of inhaled glycopyrrolate is expected to have less systemic side effects and thus can be a better alternative to systemic antisialogogue.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
70
Inclusion Criteria

ASA physical status 1 and 2 of either sex undergoing elective surgery Age of 18 to 65 years Anticipated difficult airway in which fibreoptic intubation is planned under general anaesthesia.

Exclusion Criteria

Patients in which other modalities of intubation is planned Airway obstruction.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate and compare the degree of airway secretion with or without use of inhaled glycopyrrolate prior to fibreoptic intubationIntraoperative at the time of fibreoptic intubation
Secondary Outcome Measures
NameTimeMethod
Time to reach carinaThe change in heart rate and blood pressure 20 min after nebulization

Trial Locations

Locations (1)

AIIMS Patna

🇮🇳

Patna, BIHAR, India

AIIMS Patna
🇮🇳Patna, BIHAR, India
Dr M N Pradhan
Principal investigator
9008657262
pradhanbangaloremn@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.